Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Acute Leukemia, Breast Cancer, Cancer, Desmoplastic Round Cell Sarcoma, Esophageal Andeocarcinoma, Gastric Cancer, Glioblastoma, Hodgkin Lymphoma, Mixed Phenotype AML, Non-hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Spindle Cell Sarcoma, Squamous Cell Carcinoma, Tumor, Brain, Tumor, Solid

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.

No related papers found yet.